http://www.jcog.jp/document/s_9906.pdf Web25 giu 2024 · Kato K, Muro K, Minashi K et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int. J. Radiat. Oncol. Biol. Phys. 81(3), 684–690 (2011).Crossref, Medline, CAS, Google Scholar; 5.
Multimodal treatment for resectable esophageal cancer
Web1 nov 2011 · Phase II Study of Chemoradiotherapy With 5-Fluorouracil and Cisplatin for Stage II–III Esophageal Squamous Cell Carcinoma: JCOG Trial (JCOG 9906) - ScienceDirect International Journal of Radiation Oncology*Biology*Physics Volume 81, Issue 3, 1 November 2011, Pages 684-690 Clinical Investigation Web14 lug 2011 · Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG Trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2010; [Epub ahead of … fashion outlets of chicago hotels
Transverse colon perforation in the mediastinum after
Web28 mar 2024 · We retrospectively evaluated 381 older patients (≥ 65 years) with locally advanced ESCC (stage IB/II/III, excluding T4) who received anticancer therapy at 22 medical centers in Japan. Based on age, performance status (PS), and organ function, the patients were classified into two groups: clinical trial eligible and ineligible groups. Web20 giu 2007 · 15137 Background: The study objective was to evaluate the efficacy and toxicity of chemoradiotherapy (CRT) with cisplatin and 5- fluorouracil (5FU) in patients with stage II, III ESCC. Methods: Patients with clinical stage II or III (T1N1 or T2–3N0–1 and M0) thoracic ESCC, age of 70 or younger, preserved organ functions were eligible. Treatment … WebCreated Date: 2/10/2016 3:57:28 PM free wordscapes online